APCCC 2024 | Advances in salvage radiotherapy for prostate cancer

Barbara Jereczek-Fossa, MD, PhD, University of Milan, Milan, Italy, discusses the latest advances in salvage radiotherapy for prostate cancer. Ongoing and published randomized trials are addressing key questions in the field. Current data suggest the value of adding systemic therapy, particularly for patients with higher prostate-specific antigen (PSA) levels. Additionally, ongoing trials are exploring technical aspects such as treatment volumes and fractionation, with promising results for hypofractionation, which was previously used primarily in primary treatment. This interview took place at the 2024 Advanced Prostate Cancer Consensus Conference (APCCC) in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.